|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Laparoscopic liver resection under hemihepatic vascular inflow occlusion using the lowering of hilar plate approach显示文摘BACKGROUND: With advances in technology, laparoscopic liver resection is widely accepted. Laparoscopic liver resection under hemihepatic vascular inflow occlusion has advantages over the conventional total hepatic inflow occlusion using the Pringle's maneuver, especially in patients with cirrhosis.METHOD: From November 2011 to August 2012, eight consecutive patients underwent laparoscopic liver resection under hemihepatic vascular inflow occlusion using the lowering of hilar plate approach with biliary bougie assistance.RESULTS: The types of liver resection included right hepatectomy(n1), right posterior sectionectomy(n1), left hepatectomy and common bile duct exploration(n1), segment 4b resection(n1), left lateral sectionectomy(n2), and wedge resection(n2). Four patients underwent right and 4 left hemihepatic vascular inflow occlusion. Four patients had cirrhosis. The mean operation time was 176.3 minutes. The mean time taken to achieve hemihepatic vascular inflow occlusion was 24.3minutes. The mean duration of vascular inflow occlusion was54.5 minutes. The mean intraoperative blood loss was 361 mL.No patient required blood transfusion. Postoperatively, one patient developed bile leak which healed with conservative treatment. No postoperative liver failure and mortality occurred. The mean hospital stay of the patients was 7 days.CONCLUSION: Our technique of hemihepatic vascular inflow vascular occlusion using the lowering of hilar plate approachwas safe, and it improved laparoscopic liver resection by minimizing blood loss during liver parenchymal transection. | Ying-Jun Chen Zuo-Jun Zhen Huan-Wei Chen Eric CH Lai Fei-Wen Deng Qing-Han Li Wan Yee Lau | 2014 | Hepatobiliary & Pancreatic Diseases International2014，13，5： | 23 |
| 2 | Optimal central venous pressure during partial hepatectomy for hepatocellular carcinoma显示文摘BACKGROUND:Low central venous pressure(CVP) affects hemodynamic stability and tissue perfusion.This prospective study aimed to evaluate the optimal CVP during partial hepatectomy for hepatocellular carcinoma(HCC).METHODS:Ninety-seven patients who underwent partial hepatectomy for HCC had their CVP controlled at a level of 0 to 5 mmHg during hepatic parenchymal transection.The systolic blood pressure(SBP) was maintained,if possible,at 90 mmHg or higher.Hepatitis B surface antigen was positive in 90 patients(92.8%) and cirrhosis in 84 patients(86.6%).Pringle maneuver was used routinely in these patients with clamp/unclamp cycles of 15/5 minutes.The average clamp time was 21.4±8.0 minutes.These patients were divided into 5 groups based on the CVP:group A:0-1 mmHg;B:1.1-2 mmHg;C:2.1-3 mmHg;D:3.1-4 mmHg and E:4.1-5 mmHg.The blood loss per transection area during hepatic parenchymal transection and the arterial blood gas before and after liver transection were analyzed.RESULTS:With active fluid load,a constant SBP ≥90 mmHg which was considered as optimal was maintained in 18.6% in group A(95% CI:10.8%-26.3%);39.2% in group B(95% CI:29.5%-48.9%);72.2% in group C(95% CI:63.2%-81.1%);89.7% in group D(95% CI:83.6%-95.7%);and 100% in group E(95% CI:100%-100%).The blood loss per transection area during hepatic parenchymal transection decreased with a decrease in CVP.Compared to groups D and E,blood loss in groups A,B and C was significantly less(analysis of variance test,P<0.05).Compared with the baseline,the blood oxygenation decreased significantly when the CVP was reduced.Base excess and HCO 3-in groups A and B were significantly decreased compared with those in groups C,D and E(P<0.05).CONCLUSION:In consideration of blood loss,SBP,base excess and HCO 3-,a CVP of 2.1-3 mmHg was optimal in patients undergoing partial hepatectomy for HCC. | Cheng-Xin Lin Ya Guo Wan Yee Lau Guang-Ying Zhang Yi-Ting Huang Wen-Zheng He Eric CH Lai | 2013 | Hepatobiliary & Pancreatic Diseases International2013，12，5： | 19 |
| 3 | Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma:a randomized comparative study显示文摘Background:Both portal vein embolization(PVE)and associating liver partition and portal vein ligation for staged hepatectomy(ALPPS)have merits and demerits when used in patients with unresectable liver cancers due to insufficient volumes in future liver remnant(FLR).Methods:This study was a single-center,prospective randomized comparative study.Patients with the diagnosis of hepatitis B related hepatocellular carcinoma(HCC)were randomly assigned in a 1:1 ratio to the 2 groups.The primary endpoints were tumor resection and three-year overall survival(OS)rates.Results:Between November 2014 to June 2016,76 patients with unresectable HBV-related HCC due to inadequate volume of FLR were randomly assigned to ALPPS groups(n=38)and TACE+PVE groups(n=38).Thirty-seven patients(97.4%)in the ALPPS group compared with 25 patients(65.8%)in the TACE+PVE group were able to undergo staged hepatectomy(risk ratio 1.48,95%CI:1.17-1.87,P<0.001).The three-year OS rate of the ALPPS group(65.8%)(95%CI:50.7-80.9)was significantly better than the TACE+PVE group(42.1%)(95%CI:26.4-57.8)(HR 0.50,95%CI:0.26-0.98,two-sided P=0.036).However,no significant difference in the OS rates between patients who underwent tumor resection in the 2 groups of patients was found(HR 0.80,95%CI:0.35-1.83,two-sided P=0.595).Major postoperative complications rates after the stage-2 hepatectomy were 54.1%in the ALPPS group and 20.0%in the TACE+PVE group(risk ratio 2.70,95%CI:1.17-6.25,P=0.007).Conclusions:ALPPS resulted in significantly better intermediate-term OS outcomes,at the expenses of a significantly higher perioperative morbidity rate compared with TACE+PVE in patients who had initially unresectable HBV-related HCC. | Peng-Peng Li Gang Huang Ning-Yang Jia Ze-Ya Pan Hui Liu Yun Yang Cheng-Jian He Wan Yee Lau Ye-Fa Yang Wei-Ping Zhou | 2022 | Hepatobiliary Surgery and Nutrition2022，11，1： | 16 |
| 4 | Associating liver partition and portal vein ligation for staged hepatectomy: the current role and development显示文摘BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy(ALPPS) has recently been developed to induce rapid liver hypertrophy and reduce posthepatectomy liver failure in patients with insufficient future liver remnant(FLR). ALPPS is still considered to be in an early developmental phase because surgical indications and techniques have not been standardized. This article aimed to review the current role and future developments of ALPPS.DATA SOURCES: Studies were identified by searching MEDLINE and Pub Med for articles from January 2007 to October 2016 using the keywords 'associating liver partition and portal vein ligation for staged hepatectomy' and 'ALPPS'. Additional papers were identified by a manual search of references from key articles.RESULTS: ALPPS induces more hypertrophy of the FLR in less time than portal vein embolization or portal vein ligation.The benefits of ALPPS include rapid hypertrophy 47%-110% of the liver over a median of 6-16.4 days, and 95%-100% completion rate of the second stage of ALPPS. The main criticisms of ALPPS are centered on its high morbidity and mortality rates. Morbidity rates after ALPPS have been reported to be 15.3%-100%, with ≥ the Clavien-Dindo grade III morbidity of 13.6%-44%. Mortality rates have been reported to be 0%-29%.The important questions to ask even if oncologic long-term results are acceptable are: whether the gain in quality and quantity of life can be off balance by the substantial risks of morbidity and mortality, and whether stimulation of rapid liver hypertrophy also accelerates rapid tumor progression and spread. Up till now, the documentations of the ALPPS procedure come mainly from case series, and most of these series include heterogeneous groups of malignancies. The numbers are also too small to separately evaluate survival for different tumor etiologies.CONCLUSIONS: Currently, knowledge on ALPPS is limited, and prospective randomized studies are lacking. From the reported preliminary results, safety of the ALPPS procedure remains questionable. ALPPS should only be used in experienced, high-volume hepatobiliary centers. | Wan Yee Lau Eric CH Lai Stephanie HY Lau | 2017 | Hepatobiliary & Pancreatic Diseases International2017，16，1： | 16 |
| 5 | Modifications of ALPPS–from complex to more complex or from complex to less complex operations显示文摘BACKGROUND:Associating liver partition and portal vein ligation for staged hepatectomy(ALPPS) has recently been developed to induce rapid liver hypertrophy to reduce the chance of post-hepatectomy liver failure in patients with borderline or insufficient future liver remnant.ALPPS is still in an early developmental stage and its techniques have not been standardized.This study aimed to review the technical modifications of the conventional ALPPS procedure.DATA SOURCES:Studies were identified by searching MEDLINE and Pub Med for articles published from January 2007 to December 2016 using the keywords 'associating liver partition and portal vein ligation for staged hepatectomy' and 'ALPPS'.Additional articles were identified by a manual search of references from key articles.RESULTS:There have been a lot of modifications of the conventional ALPPS.These are classified as:(1) modifications aiming to improve surgical results;(2) modifications aiming to expand surgical indications;(3) salvage ALPPS;(4) ALPPS using the minimally invasive approach.Some of these modifications have made the conventional ALPPS procedure to become even more complex,although there have also been other attempts to make the procedure less complex.The results of most of these modifications have been reported in small case series or case reports.We need better well-designed studies to establish the true roles of these modifications.However,it is interesting to see how this conventional ALPPS procedure has evolved since its introduction.CONCLUSIONS:There is a trend for the use of minimally invasive procedure in the phase 1 or 2 of the conventional ALPPS procedure.Some of these modifications have expanded the use of ALPPS in patients who have been considered to have unresectable liver tumors.The long-term oncological outcomes of these modifications are still unknown. | Wan Yee Lau Eric CH Lai | 2017 | Hepatobiliary & Pancreatic Diseases International2017，16，4： | 7 |
| 6 | Current therapy of hilar cholangiocarcinoma显示文摘BACKGROUND: Hilar cholangiocarcinoma (HC) is an adeno-carcinoma of the extrahepatic biliary tree arising from the main left or right hepatic ducts or their confluence. This tumor is still considered to be difficult to treat or to cure. DATA SOURCES: We reviewed the medical literature on HC. Relevant and updated information on this tumor was analyzed in a concise and easy-to-read manner. The article is not intended to be a systematic review, but an extensive search was conducted on PubMed and MEDLINE using the keywords 'hilar cholangiocarcinoma' and 'Klatskin tumor' until July 2011. RESULTS: The selection and the timing of management options for patients with HC are determined by the degree of certainty of the diagnosis, the general condition of the patients, the underlying liver function and the stage of the disease. Current treatment of HC can be divided into curative and palliative treatment. For the curative treatment, local excision should only be used on small tumors which are confined to the bile duct wall and Bismuth I papillary carcinoma. Partial hepatectomy should be combined with caudate lobe resection and porta-hepatis lymph node dissection. The results of these major resections can be improved with portal vein embolization, and staging laparoscopy and laparoscopic ultrasound. The role of preoperative biliary drainage is controversial. Autotransplantation for HC gave disappointing results while the Mayo Protocol of chemoradiation for selecting patients with unresectable HC for orthotopic liver transplantation has been widely accepted. Palliative treatment included bypass surgery, endoscopic or percutaneous stenting, photodynamic therapy, intraluminal brachytherapy, and external radiation and systemic therapy. CONCLUSIONS: Adequate surgery with R0 resection should be the main goal of treatment. For patients with unresectable HC, treatment aims to improve the quality and quantity of their survival. | Stephanie Hiu Yan Lau Wan Yee Lau | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，1： | 6 |
| 7 | A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus显示文摘Background:Hepatic vein tumor thrombus(HVTT)is a significant poor risk factor for survival outcomes in hepatocellular carcinoma(HCC)patients.Currently,the widely used international staging systems for HCC are not refined enough to evaluate prognosis for these patients.A new classification for macroscopic HVTT was established,aiming to better predict prognosis.Methods:This study included 437 consecutive HCC patients with HVTT who underwent different treatments.Overall survival(OS)and time-dependent receiver operating characteristic(ROC)curve area analysis were used to determine the prognostic capacities of the new classification when compared with the different currently used staging systems.Results:The new HVTT classification was defined as:type I,tumor thrombosis involving hepatic vein(HV),including microvascular invasion;type II,tumor thrombosis involving the retrohepatic segment of inferior vena cava;and type III,tumor thrombosis involving the supradiaphragmatic segment of inferior vena cava.The numbers(percentages)of patients with types I,II,and III HVTT in the new classification were 146(33.4%),143(32.7%),and 148(33.9%),respectively.The 1-,2-,and 3-year OS rates for types I to III HVTT were 79.5%,58.6%,and 29.1%;54.8%,23.3%,and 13.8%;and 24.0%,10.0%,and 2.1%,respectively.The time-dependent-ROC curve area analysis demonstrated that the predicting capacity of the new HVTT classification was significantly better than any other staging systems.Conclusions:A new HVTT classification was established to predict prognosis of HCC patients with HVTT who underwent different treatments.This classification was superior to,and it may serve as a supplement to,the commonly used staging systems. | Zhen-Hua Chen Kang Wang Xiu-Ping Zhang Jing-Kai Feng Zong-Tao Chai Wei-Xing Guo Jie Shi Meng-Chao Wu Wan Yee Lau Shu-Qun Cheng | 2020 | Hepatobiliary Surgery and Nutrition2020，9，6： | 5 |
| 8 | The current role of radiofrequency ablation in the treatment of hepatocellular carcinoma显示文摘Local ablative therapy is used in treating liver tumors by either injection of cytotoxic agents(chemicals,radioactive isotopes,hyperthermic agents or chemotherapeutic agents)or application of an energy source to achieve thermal ablation,cryoablation or conformal external beam radiation(Table 1). | Wan Yee Lau Stephanie Hiu Yan Lau | 2017 | Hepatobiliary & Pancreatic Diseases International2017，16，2： | 5 |
| 9 | Posthepatectomy HBV Reactivation in Hepatitis B–Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA Levels显示文摘 | Gang Huang Eric C. H. Lai Wan Yee Lau Wei-ping Zhou Feng Shen Ze-ya Pan Si-yuan Fu Meng-chao Wu | 2013 | Annals of Surgery2013，，3： | 5 |
| 10 | Surgical Resection Versus Conformal Radiotherapy Combined With TACE for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Comparative Study显示文摘 | Qing-he Tang Ai-jun Li Guang-ming Yang Eric C.H. Lai Wei-ping Zhou Zhi-hao Jiang Wan Yee Lau Meng-chao Wu | 2013 | World Journal of Surgery2013，，6： | 4 |
| 11 | Surgical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus显示文摘 | Jie Shi Eric C. H. Lai Nan Li Wei-Xing Guo Jie Xue Wan Yee Lau Meng-Chao Wu Shu-Qun Cheng | 2010 | Annals of Surgical Oncology2010，，8： | 4 |
| 12 | A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus显示文摘Background:A new staging system for patients with hepatocellular carcinoma(HCC)associated with portal vein tumor thrombus(PVTT)was developed by incorporating the good points of the BCLC classification of HCC,and by improving on the currently existing classifications of HCC associated with PVTT.Methods:Univariate and multivariate analysis with Waldχ2 test were used to determinate the clinical prognostic factors for overall survival(OS)in patients with HCC and PVTT in the training cohort.Then the conditional inference trees analysis was applied to establish a new staging system.Results:A training cohort of 2,179 patients from the Eastern Hepatobiliary Surgery Hospital and a validation cohort of 1,550 patients from four major liver centers in China were enrolled into establishing and validating a new staging system.The system was established by incorporating liver function,general health status,tumor resectability,extrahepatic metastasis and extent of PVTT.This staging system had a good discriminatory ability to separate patients into different stages and substages.The median OS for the two cohorts were 57.1(37.2-76.9),12.1(11.0-13.2),5.7(5.1-6.2),4.0(3.3-4.6)and 2.5(1.7-3.3)months for the stages 0 to IV,respectively(P<0.001)in the training cohort.The corresponding figures for the validation cohort were 6.4(4.9-7.9),2.8(1.3-4.4),10.8(9.3-12.4),and 1.5(1.3-1.7)months for the stages II to IV,respectively(P<0.001).The mean survival for stage 0 to 1 were 37.6(35.9-39.2)and 30.4(27.4-33.4),respectively(P<0.001).Conclusions:A new staging system was established which provided a good discriminatory ability to separate patients into different stages and substages after treatment.It can be used to supplement the other HCC staging systems. | Wan Yee Lau Kang Wang Xiu-Ping Zhang Le-Qun Li Tian-Fu Wen Min-Shan Chen Wei-Dong Jia Li Xu Jie Shi Wei-Xing Guo Ju-Xian Sun Zhen-Hua Chen Lei Guo Xu-Biao Wei Chong-De Lu Jie Xue Li-Ping Zhou Ya-Xing Zheng Meng Wang Meng-Chao Wu Shu-Qun Cheng | 2021 | Hepatobiliary Surgery and Nutrition2021，10，6： | 3 |
| 13 | Liver resection versus intensity-modulated radiation therapy for treatment of hepatocellular carcinoma with hepatic vein tumor thrombus:a propensity score matching analysis显示文摘Background:The presence of hepatic vein tumor thrombus(HVTT)is a major determinant of survival outcomes in hepatocellular carcinoma(HCC)patients.This study compared survival outcomes between liver resection(LR)and intensity-modulated radiation therapy(IMRT)in HCC patients with HVTT.Methods:Data from patients who underwent LR or IMRT for HCC with HVTT at the Eastern Hepatobiliary Surgery Hospital were retrospectively analyzed.Their survival outcomes were compared before and after propensity score matching(PSM).Results:Three hundred and seven HCC patients with HVTT who underwent either LR(n=140)or IMRT(n=167)were enrolled.PSM matched 82 pairs of patients.The overall survival(OS)and recurrence-free survival(RFS)rates were significantly higher for patients in the LR group than those in the IMRT group.On subgroup analysis,significantly better survival outcomes were obtained after LR than IMRT in patients with peripheral type of HVTT(pHVTT)and major type of HVTT(mHVTT).However,similar survival outcomes were obtained after LR and IMRT when the HVTT had developed into inferior vena cava tumor thrombus(IVCTT).Conclusions:LR resulted in significantly better survival outcomes in HCC patients with HVTT when compared to IMRT.Once the HVTT had developed IVCTT,LR and IMRT resulted in similarly bad survival outcomes. | Zhen-Hua Chen Xiu-Ping Zhang Shuang Feng Jing-Kai Feng Zong-Tao Chai Wei-Xing Guo Jie Shi Wan Yee Lau Yan Meng Shu-Qun Cheng | 2021 | Hepatobiliary Surgery and Nutrition2021，10，5： | 3 |
| 14 | Typing of biliary tumor thrombus influences the prognoses of patients with hepatocellular carcinoma显示文摘Objective:To establish a new classification of biliary tumor thrombus(BTT).Methods:Overall survival of patients with BTT was first used to determine whether it correlated with current hepatocellular carcinoma staging systems.Univariate and multivariate analyses were used to determine factors affecting the overall survival(OS)to form the basis of our new classification for BTT.Results:All 6 international staging systems showed overlapping survival curves.Univariate followed by multivariate analyses showed that total bilirubin and intrahepatic/extrahepatic BTT were significant risk factors of OS.Based on these data,a new BTT classification was defined as:TypeⅠ:intrahepatic BTT;and TypeⅡ:extrahepatic BTT involving a common bile duct or common hepatic duct.TypeⅠwas further subdivided into type Ia:BTT involving a second-order intrahepatic duct or above,and type Ib:BTT involving a first-order intrahepatic duct.TypeⅡwas further subdivided into typeⅡa and typeⅡb using a cut-off total bilirubin(TB)>300μmol/L.The numbers(percentages)of patients with typesⅠandⅡBTT were 69(34.2%)and 133(65.8%),respectively.The median OS of typeⅠpatients was significantly higher than that of typeⅡpatients(37.5 months vs.23.2 months;P=0.002).Using subgroup analyses,OS outcomes were significantly different between the subgroups of typeⅡb and type IIa,although there was no significant difference between the type Ia and type Ib subgroups(P=0.07).Conclusions:A new BTT classification was established to predict prognoses of HCC patients with BTT who underwent liver resection. | Juxian Sun Jiayi Wu Chang Liu Jie Shi Yonggang Wei Jianyin Zhou Zhibo Zhang Wan Yee Lau Maolin Yan Shuqun Cheng | 2021 | Cancer Biology & Medicine2021，18，3： | 3 |
| 15 | Partial Hepatectomy versus Transcatheter Arterial Chemoembolization for Resectable Multiple Hepatocellular Carcinoma Beyond Milan Criteria: A RCT显示文摘 | Lei Yin Hui Li Ai-Jun Li Wan Yee Lau Ze-ya Pan Eric C.H. Lai Meng-chao Wu Wei-ping Zhou | 2014 | Journal of Hepatology2014，，： | 3 |
| 16 | Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for Resectable Hepatocellular Carcinoma: A Prospective Randomized Trial—Update on 5-Year and 10-Year Survival显示文摘 | Wan Yee Lau Eric C. H. Lai Thomas W. T. Leung Simon C. H. Yu | 2008 | Annals of Surgery2008，，1： | 3 |
| 17 | Hepatectomy for Bilateral Primary Hepatolithiasis: A Cohort Study显示文摘 | Tian Yang Wan Yee Lau Eric C. H. Lai Li-Qun Yang Jin Zhang Guang-Shun Yang Jun-Hua Lu Meng-Chao Wu | 2010 | Annals of Surgery2010，，1： | 3 |
| 18 | Impact of pathological response after preoperative transcatheter arterial chemoembolization(TACE)on incidences of microvascular invasion and early tumor recurrence in hepatocellular carcinoma:a multicenter propensity score matching analysis显示文摘Background:To study the influence of pathological responses(PR)after transcatheter arterial chemoembolization(TACE)on incidences of microvascular invasion(MVI)and early recurrence in hepatocellular carcinoma(HCC)patients.Methods:Between 2013 to 2015,consecutive HCC patients who underwent liver resection with“curative”intent at three hospitals were enrolled in this study.Patients with different areas of PR after preoperative TACE were compared with those without preoperative TACE on the incidences of MVI,early recurrence rates and patterns of recurrence before and after propensity score matching(PSM).Results:Of 1,970 patients,737 patients who received preoperative TACE were divided into three groups according to the areas of PR:≥90%(n=226),60-90%(n=447),and<60%(n=64).PR≥90%was an independent protective factor of incidences of MVI[odds ratio(OR),0.144;95%confidence interval(CI),0.082-0.245,P<0.001)and early recurrence(HR,0.742;95%CI,0.561-0.963,P=0.032);while PR<60%was an independent risk factor of incidences of MVI(OR,6.076;95%CI,3.004-11.728,P<0.001)and early recurrence(HR,1.428;95%CI,1.095-1.929;P=0.009).Furthermore,patients with PR<60%were significantly more likely to develop multiple intrahepatic recurrences involving multiple hepatic segments when compared with patients without preoperative TACE.Conclusions:This study indicated the area of PR after TACE was closely associated with the incidences of MVI and early tumor recurrence.Patients with PR<60%were at significantly higher risks of having more MVI,early and multiple tumor recurrences. | Yun Yang Zheng Dang Peng Lu Youwen Qian Kongying Lin Zeya Pan Wan Yee Lau Weiping Zhou | 2022 | Hepatobiliary Surgery and Nutrition2022，11，3： | 2 |
| 19 | Surgical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus显示文摘 | Jie Shi MD Eric C. H. Lai MBChB MRCS(Ed) FRACS Nan Li MD Wei-Xing Guo MD Jie Xue MD Wan Yee Lau MD FRCS FACS FRACS(Hon) Meng-Chao Wu MD Shu-Qun Cheng MD | 2010 | Annals of Surgical Oncology2010，，8： | 2 |
| 20 | Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma:a multi-center propensity score matched analysis of real-world practice显示文摘Background:To compare the treatment effectiveness and safety among transarterial infusion chemotherapy(TAI)with FOLFOX regimen,transarterial chemoembolization(TACE),and sorafenib in patients with BCLC stage C hepatocellular carcinoma(HCC).Methods:The data of consecutive patients with BCLC stage C HCC treated with TAI,TACE,or sorafenib from January 2015 to December 2018 at three centers were retrospectively analyzed.Propensity-score matched(PSM)analysis was pairwise performed to reduce selection bias.Treatment effectiveness and safety were evaluated and compared using the Kaplan-Meier method,log-rank test,Cox regression models,andχ2 test.Results:The median overall survival(OS)in the matched TAI cohort was significantly longer than the sorafenib cohort(19.6 vs.7.5 months,P=0.009),and the TACE cohort(estimated 27.8 vs.6.6 months,P<0.001).The difference in median progression-free survival(PFS)between the matched TAI and sorafenib cohorts was not significant(5.8 vs.2.3 months,P=0.219).The median PFS in the matched TAI cohort was significantly longer than the TACE cohort(6.5 vs.2.8 months,P<0.001).The objective response rate(ORR)in the matched TAI cohort was significantly higher than the sorafenib cohort(36.4%vs.0.0%,P<0.001)and the TACE cohort(48.7%vs.4.7%,P<0.001).The incidences of adverse events(AEs)were similar among these three cohorts.Conclusions:TAI with FOLFOX regimen was an effective and safe therapy that improved survival of patients with BCLC stage C HCC. | Shaohua Li Jie Mei Qiaoxuan Wang Feng Shi Hongyan Liu Ming Zhao Lianghe Lu Yihong Ling Zhixing Guo Yabing Guo Xiaoming Chen Ming Shi Wan Yee Lau Wei Wei Rongping Guo | 2021 | Hepatobiliary Surgery and Nutrition2021，10，5： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员